Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Obsidian TherapeuticsOBX -0.06%11 EV-to-EBIT is 8.28 as of Sep. 22, 2026. GuruFocus rates OBX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 381 Biotechnology companies, Obsidian Therapeutics ranks better than 59.84% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Obsidian Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $300.41 Mil.
Obsidian Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $124.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Obsidian Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Obsidian Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Obsidian Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Obsidian Therapeutics's EV-to-EBIT falls into.
Obsidian Therapeutics's current Enterprise Value is $1,028.34 Mil.
Obsidian Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $124.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Obsidian Therapeutics (OBX) has a EV-to-EBIT of 8.28 as of Sep. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Obsidian Therapeutics and its competitors. According to the industry distribution chart, Obsidian Therapeutics ranks #153 out of 381 companies in the Biotechnology industry, placing it in the top 40.2%.
Is Obsidian Therapeutics' EV-to-EBIT too high?
Obsidian Therapeutics' current EV-to-EBIT is 8.28. The Biotechnology industry median EV-to-EBIT is 14.08. Obsidian Therapeutics' value of 8.28 is 41.2% below this industry median. Based on the distribution chart, Obsidian Therapeutics ranks #153 out of 381 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Obsidian Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' EV-to-EBIT compare to LXRX and SLNCF?
According to the Biotechnology industry distribution chart, Obsidian Therapeutics ranks #153 out of 381 companies for EV-to-EBIT. This puts Obsidian Therapeutics in the upper half of its industry. The industry median EV-to-EBIT is 14.08. Obsidian Therapeutics' value of 8.28 is 41.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.08, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Obsidian Therapeutics's current EV-to-EBIT of 8.28 is 41.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Obsidian Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Obsidian Therapeutics's current EV-to-EBIT is 8.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current EV-to-EBIT of 8.28. The current EV-to-EBIT is 8.28 and 41.2% below the Biotechnology industry median of 14.08. Obsidian Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current EV-to-EBIT is 8.28 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States that develops engineered cell therapies for solid tumors. The company's proprietary cytoDRiVE platform uses drug-responsive domains to regulate protein function, and its lead programs apply this technology to engineered tumor-infiltrating lymphocyte (TIL) therapies, known as cytoTILs. Its main product candidate, OBX-115, is an autologous, genetically engineered TIL therapy designed to eliminate the need for systemic interleukin-2 administration, and it is being evaluated in clinical trials for melanoma and non-small cell lung cancer. Obsidian also pursues additional engineered cell therapy programs built on its platform. The company operates as a research and development-stage business, funding its activities primarily through equity financing, partnerships, and collaboration arrangements rather than product revenue, and it targets oncology markets in the United States and other regions.
11GF Score
Get the complete analysis for OBX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBX has been successfully added to your 
